National Pension Service Raises Stake in Merck & Co., Inc. $MRK

National Pension Service grew its position in Merck & Co., Inc. (NYSE:MRK) by 3.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,707,385 shares of the company’s stock after buying an additional 175,582 shares during the period. National Pension Service’s holdings in Merck & Co., Inc. were worth $479,021,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Darwin Wealth Management LLC raised its stake in shares of Merck & Co., Inc. by 237.4% in the third quarter. Darwin Wealth Management LLC now owns 307 shares of the company’s stock valued at $26,000 after acquiring an additional 216 shares in the last quarter. Kilter Group LLC acquired a new position in Merck & Co., Inc. during the 2nd quarter worth $27,000. Bare Financial Services Inc grew its stake in Merck & Co., Inc. by 51.9% during the 2nd quarter. Bare Financial Services Inc now owns 366 shares of the company’s stock worth $29,000 after purchasing an additional 125 shares in the last quarter. Barnes Dennig Private Wealth Management LLC increased its holdings in Merck & Co., Inc. by 302.3% during the 3rd quarter. Barnes Dennig Private Wealth Management LLC now owns 354 shares of the company’s stock worth $30,000 after purchasing an additional 266 shares during the period. Finally, Evolution Wealth Management Inc. acquired a new stake in Merck & Co., Inc. in the 2nd quarter valued at about $31,000. 76.07% of the stock is currently owned by hedge funds and other institutional investors.

Merck & Co., Inc. Price Performance

Merck & Co., Inc. stock opened at $110.24 on Friday. The firm has a market capitalization of $273.62 billion, a PE ratio of 14.56, a P/E/G ratio of 1.52 and a beta of 0.29. Merck & Co., Inc. has a 52 week low of $73.31 and a 52 week high of $112.90. The firm’s 50-day simple moving average is $105.20 and its 200 day simple moving average is $91.87. The company has a quick ratio of 1.44, a current ratio of 1.66 and a debt-to-equity ratio of 0.77.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings data on Tuesday, February 3rd. The company reported $1.94 earnings per share for the quarter, missing analysts’ consensus estimates of $2.08 by ($0.14). Merck & Co., Inc. had a net margin of 29.63% and a return on equity of 44.54%. On average, equities research analysts predict that Merck & Co., Inc. will post 9.01 EPS for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 7th. Shareholders of record on Monday, March 16th will be issued a $0.85 dividend. The ex-dividend date is Monday, March 16th. This represents a $3.40 dividend on an annualized basis and a yield of 3.1%. Merck & Co., Inc.’s payout ratio is currently 44.91%.

Merck & Co., Inc. News Summary

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Zacks highlights strong Keytruda demand and new product launches as key upside drivers into Q4 results, supporting longer?term revenue growth and helping sentiment today. Buy, Sell or Hold MRK Stock: Key Factors to Watch Before Q4 Earnings
• Positive Sentiment: Insider/“smart money” activity: Chirfi Guindo bought roughly $1.06M of MRK stock — a buy by an institutional insider can signal confidence and attract momentum buyers. Smart Money Move: Chirfi Guindo Grabs $1.06M Worth Of Merck & Co Stock
• Positive Sentiment: Zacks’ market recap notes MRK outperformed while the broader market dipped, indicating relative strength and sector?specific buying interest. Why the Market Dipped But Merck (MRK) Gained Today
• Neutral Sentiment: Analyst notes and sector coverage (Globe and Mail) provide mixed, mostly informational views on Merck alongside peers—useful for context but not a clear directional trigger. Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK) and Waters (WAT)
• Neutral Sentiment: Additional analyst commentary comparing MRK with UnitedHealth provides sector perspective but no new catalyst. Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK) and UnitedHealth (UNH)
• Neutral Sentiment: Zacks’ primer on Wall Street estimates and key metrics ahead of Q4 is a useful reference for modeling MRK’s upcoming quarter but doesn’t itself move the needle. Curious about Merck (MRK) Q4 Performance? Explore Wall Street Estimates for Key Metrics
• Neutral Sentiment: Zacks notes MRK is a trending stock on its platform—higher retail/institutional attention increases liquidity and volatility risk but is not a directional catalyst by itself. Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It
• Negative Sentiment: Zacks warns that declining analyst estimates and rising M&A?related costs could depress near?term results and investor sentiment—key risk ahead of earnings. Buy, Sell or Hold MRK Stock: Key Factors to Watch Before Q4 Earnings
• Negative Sentiment: Brokerage consensus is an average “Hold” rating, indicating limited near?term upgrade potential and less bullish analyst conviction. Merck & Co., Inc. (NYSE:MRK) Given Average Rating of “Hold” by Brokerages

Insider Activity at Merck & Co., Inc.

In other news, EVP David Michael Williams sold 8,614 shares of the firm’s stock in a transaction that occurred on Monday, November 3rd. The shares were sold at an average price of $83.59, for a total transaction of $720,044.26. Following the completion of the sale, the executive vice president owned 24,578 shares of the company’s stock, valued at approximately $2,054,475.02. This trade represents a 25.95% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 0.13% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the company. Deutsche Bank Aktiengesellschaft increased their target price on Merck & Co., Inc. from $110.00 to $111.00 and gave the company a “hold” rating in a report on Tuesday, November 18th. Zacks Research downgraded shares of Merck & Co., Inc. from a “hold” rating to a “strong sell” rating in a research report on Friday, January 9th. BMO Capital Markets upgraded Merck & Co., Inc. from a “market perform” rating to an “outperform” rating and upped their price target for the stock from $82.00 to $130.00 in a research note on Thursday, December 18th. TD Cowen increased their target price on Merck & Co., Inc. from $100.00 to $120.00 and gave the stock a “hold” rating in a research note on Tuesday, January 20th. Finally, Morgan Stanley upped their target price on shares of Merck & Co., Inc. from $100.00 to $102.00 and gave the stock an “equal weight” rating in a research report on Friday, December 12th. Eight equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, Merck & Co., Inc. currently has an average rating of “Hold” and a consensus price target of $114.53.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.